Latest news with #OneSource
The Hindu
2 days ago
- Business
- The Hindu
Will manufacture and export but not sell weight-loss drug in India, Dr. Reddy's tells Delhi HC
Dr. Reddy's Laboratories Ltd. and OneSource Specialty Pharma have given an undertaking before the Delhi High Court that they will neither sell nor market Novo Nordisk's anti-obesity drug Wegovy within India pending the outcome of a patent infringement lawsuit filed by the Danish pharmaceutical giant. The case concerns an alleged violation of Novo Nordisk's patent on its diabetes medication, semaglutide. Dr. Reddy's and OneSource, represented by senior advocates Abhishek Manu Singhvi and Mukul Rohatgi, respectively, informed the court that while Dr. Reddy's has been granted a licence to manufacture the contested drug in December 2024 and began production in April 2025, Dr. Reddy's currently does not hold a licence to sell the drug in India. Dr. Reddy's and OneSource gave an assurance that they will will not sell the drug in India. However, the Indian parma companies said they reserve their right to export the drug in countries where Novo Nordisk has not been granted a patent yet. These submissions were formally taken on record by the court, and the counsel for two pharma companies confirmed that the undertaking would remain binding on the company until the next hearing. Appearing for Novo Nordisk, senior advocate Sandeep Sethi argued that under the Indian Patents Act, 1970, even exporting a product that infringes a patent constitutes an act of infringement. The court, in its May 29 order, said it will consider the submission of the parties on the next date of hearing, on August 19.
Economic Times
3 days ago
- Business
- Economic Times
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Live Events Next Hearing on Aug 19 (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
3 days ago
- Business
- Time of India
Big Fat Legal War Bursts Out aheadof Wegovy Launch
Live Events A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weight-loss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have a licence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide— the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide.'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
3 days ago
- Business
- Time of India
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is scheduled for August 19. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Next Hearing on Aug 19 A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy semaglutide ) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Associated Press
26-03-2025
- Business
- Associated Press
OneSource Expands Background Screening Services with Social Media Screening
Enhancing hiring confidence with AI-powered social media screening to identify risks, and protect workplace culture. 'Social media screening enables organizations to proactively assess risks that may not be evident through conventional background checks.' — Nathan Laing, Founder and CEO of OneSource WINCHESTER, VA, UNITED STATES, March 26, 2025 / / -- OneSource, a leading provider of employment background screening solutions, is enhancing its service offerings with the addition of comprehensive social media screening. This new solution provides organizations with deeper insights into candidates' online behavior, helping them make more informed hiring decisions while safeguarding their workplace culture and brand reputation. Social media screening allows employers to go beyond traditional background checks by analyzing publicly available online activity to identify potential risk factors such as violent or threatening behavior, discrimination, illegal activity, and other inappropriate content. By incorporating advanced technology, OneSource is offering a thorough, compliant, and efficient method for evaluating online conduct without introducing hiring bias. 'We continuously seek ways to equip our clients with the most modern and effective screening tools available,' said Nathan Laing, Founder and CEO of OneSource. 'Social media screening enables organizations to proactively assess potential risks that may not be evident through conventional background checks, helping them make hiring decisions with confidence and peace of mind.' This new service is particularly valuable for industries where brand reputation, customer trust, and workplace safety are critical, such as healthcare, education, finance, and public-facing roles. OneSource's social media screening solution is designed to align with Fair Credit Reporting Act (FCRA) and Equal Employment Opportunity Commission (EEOC) guidelines, ensuring compliance and ethical data usage. By leveraging cutting-edge technology, OneSource continues to enhance its suite of background screening solutions, enabling businesses to hire with greater confidence while mitigating potential risks associated with online behavior. About OneSource OneSource, Inc. is a trusted provider of comprehensive background screening solutions, helping businesses make informed hiring decisions with confidence. With over two decades of industry experience, OneSource delivers cutting-edge technology, compliance expertise, and a commitment to exceptional customer service. From identity verification to criminal record searches and compliance-driven screenings, OneSource empowers organizations across industries to build safer workplaces. To learn more, visit Laura Curtis Legal Disclaimer:
